Frequency of three BRCA1 gene founder mutations in breast/ovarian cancer families from the Pomerania–Kujawy region of Poland
Article first published online: 18 NOV 2003
DOI: 10.1046/j.1399-0004.2003.00178.x
Additional Information
How to Cite
Janiszewska, H., Haus, O., Lauda-Świeciak, A., Pasińska, M., Laskowski, R., Szymański, W., Górski, B. and Lubiński, J. (2003), Frequency of three BRCA1 gene founder mutations in breast/ovarian cancer families from the Pomerania–Kujawy region of Poland. Clinical Genetics, 64: 502–508. doi: 10.1046/j.1399-0004.2003.00178.x
Publication History
- Issue published online: 18 NOV 2003
- Article first published online: 18 NOV 2003
- Received 9 May 2003, revised and accepted for publication 22 August 2003
- Abstract
- Article
- References
- Cited By
Keywords:
- founder BRCA1 mutations;
- hereditary breast;
- ovarian cancer
A group of 63 families from the Pomerania–Kujawy region were analyzed for three BRCA1 gene Polish founder mutations, 5382insC, 300T>G, and 4153delA, because of breast (BrCa) and/or ovarian cancer (OvCa) history. The analysis was carried out by multiplex polymerase chain reaction method. BRCA1 mutation was revealed in nine (14%) families: in three (33%) of hereditary BrCa and OvCa families, in three (8%) of hereditary BrCa families, and in three (21%) of hereditary OvCa families. According to risk criteria, it was revealed in 45% of high-risk families with more than three cancers, 13% of moderate-risk families with two cancers, and 8% of families with sporadic OvCa. In six families, the mutation was found in a proband with BrCa or OvCa and in three families, the mutation was found in a healthy proband, first-degree relative of a patient deceased of BrCa or OvCa. 5382insC frameshift mutation accounted for 67% and 300T>G missense mutation for 33% of all identified familial mutations. 4153delA frameshift mutation was not found in analyzed sample of families. 5382insC mutation was found in 9% and 300T>G in 5% of all investigated families, and in 27 and 18%, respectively, of high-risk families. This underlines the importance of applying strict inclusion criteria to analyze mutation frequency in hereditary BrCa/OvCa families.

1399-0004/asset/olbannerleft.gif?v=1&s=f4df12fcfdddd9e4e4f23e893fc19413602f3e2e)
1399-0004/asset/olbannerright.gif?v=1&s=679f4ac6faa8ea7552ef0d2445fd911f67c53053)
1399-0004/asset/cover.gif?v=1&s=8bada1cac0540098302efec87fd786c08663a2e3)